Curanex Pharmaceuticals (CURX) Retained Earnings (2024 - 2026)

Curanex Pharmaceuticals (CURX) has reported Retained Earnings for 3 consecutive years, with -$11.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings fell 1276.04% year-over-year to -$11.3 million; the trailing twelve-month figure through Jun 2026 stood at -$11.3 million (down 1276.04% YoY), and the FY2025 full-year result was -$4.8 million, down 678.79% from the prior year.
• Retained Earnings retreated to -$11.3 million in Q2 2026 per CURX's latest filing, from -$4.8 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$622449.0 in Q4 2024 and bottomed at -$11.3 million in Q2 2026.
• Historically, Retained Earnings has averaged -$3.9 million across 3 years, with a median of -$1.8 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Retained Earnings plunged 678.79% in 2025, then sank 1276.04% in 2026.
• Over 3 years, Retained Earnings stood at -$622449.0 in 2024, then slumped by 678.79% to -$4.8 million in 2025, then tumbled by 132.88% to -$11.3 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$11.3 million, -$4.8 million, and -$1.8 million for Q2 2026, Q4 2025, and Q3 2025 respectively.